{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:42:49Z","timestamp":1759693369861,"version":"build-2065373602"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.mehy.2021.110537","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T06:48:44Z","timestamp":1613544524000},"page":"110537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Old drug, new Trick? The rationale for the treatment of COVID-19 with activated protein C"],"prefix":"10.1016","volume":"149","author":[{"given":"Steven B.","family":"Pestka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2021.110537_b0005","article-title":"Dexamethasone in hospitalized patients with Covid-19 - preliminary report","author":"RECOVERY Collaborative Group","year":"2020","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.mehy.2021.110537_b0010","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"ACTT-1 study group members. remdesivir for the treatment of Covid-19 - final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.mehy.2021.110537_b0015","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.mehy.2021.110537_b0020","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","article-title":"BACC Bay Tocilizumab Trial Investigators. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19","volume":"383","author":"Stone","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mehy.2021.110537_b0025","unstructured":"Coronavirus Disease 2019 (COVID-19) Treatment Guidelines, National Institutes of Health, Available at: https:\/\/www.covid19treatmentguidelines.nih.gov. Accessed January 19, 2021."},{"key":"10.1016\/j.mehy.2021.110537_b0030","unstructured":"COVID-19 Therapeutics Prioritized for Testing in Clinical Trials, National Institutes of Health, Available at: https:\/\/www.nih.gov\/research-training\/medical-research-initiatives\/activ\/covid-19-therapeutics-prioritized-testing-clinical-trials. Accessed January 20, 2021."},{"key":"10.1016\/j.mehy.2021.110537_b0035","unstructured":"A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults With COVID-19, ClinicalTrials.gov Number NCT04505774, Available at https:\/\/fnih.org\/sites\/default\/files\/final\/activ-4a.pdf. Accessed January 18, 2021."},{"issue":"14","key":"10.1016\/j.mehy.2021.110537_b0040","doi-asserted-by":"crossref","first-page":"7944","DOI":"10.1016\/S0021-9258(18)34276-5","article-title":"Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation","volume":"257","author":"Esmon","year":"1982","journal-title":"J Biol Chem"},{"issue":"43","key":"10.1016\/j.mehy.2021.110537_b0045","doi-asserted-by":"crossref","first-page":"25336","DOI":"10.1074\/jbc.270.43.25336","article-title":"Protein C inhibitor is a potent inhibitor of the thrombin-thrombomodulin complex","volume":"270","author":"Rezaie","year":"1995","journal-title":"J Biol Chem."},{"issue":"6","key":"10.1016\/j.mehy.2021.110537_b0050","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1182\/blood.V97.6.1685","article-title":"Endothelial cell protein C receptor plays an important role in protein C activation in vivo","volume":"97","author":"Taylor","year":"2001","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.mehy.2021.110537_b0055","doi-asserted-by":"crossref","first-page":"10212","DOI":"10.1073\/pnas.93.19.10212","article-title":"The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex","volume":"93","author":"Stearns-Kurosawa","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.mehy.2021.110537_b0060","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1056\/NEJM199905203402007","article-title":"Vascular-bed specific hemostasis and hypercoagulable states","volume":"340","author":"Rosenberg","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mehy.2021.110537_b0065","unstructured":"Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol."},{"key":"10.1016\/j.mehy.2021.110537_b0070","doi-asserted-by":"crossref","first-page":"18735","DOI":"10.1016\/S0021-9258(17)32228-7","article-title":"Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa","volume":"269","author":"Shen","year":"1994","journal-title":"J Biol Chem."},{"key":"10.1016\/j.mehy.2021.110537_b0075","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1097\/00003246-200107001-00018","article-title":"Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation","volume":"29","author":"Esmon","year":"2001","journal-title":"Crit. Care Med"},{"key":"10.1016\/j.mehy.2021.110537_b0080","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1073\/pnas.83.10.3460","article-title":"Interleukin-1 induces endothelial cell procoagulant while suppressing cell surface anticoagulant activity","volume":"83","author":"Nawroth","year":"1986","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.mehy.2021.110537_b0085","doi-asserted-by":"crossref","first-page":"7400","DOI":"10.1084\/jem.163.3.740","article-title":"Modulation of endothelial cell hemostatic properties by tumor necrosis factor","volume":"163","author":"Nawroth","year":"1986","journal-title":"J Exp Med"},{"key":"10.1016\/j.mehy.2021.110537_b0090","doi-asserted-by":"crossref","unstructured":"Archipoff G, Beretz A, Freyssinet JM, Klein-Soyer C, Brisson C, Cazenave JP. Heterogeneous regulation of constitutive thrombomodulin or inducible tissue-factor activities on the surface of human saphenous-vein endothelial cells in culture following stimulation by interleukin-1, tumour necrosis factor, thrombin or phorbol ester. Biochem J. 1991;273(Pt 3)(Pt 3):679\u2013684.","DOI":"10.1042\/bj2730679"},{"issue":"1","key":"10.1016\/j.mehy.2021.110537_b0095","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/blood.V73.1.159.159","article-title":"Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture","volume":"73","author":"Moore","year":"1989","journal-title":"Blood"},{"issue":"42","key":"10.1016\/j.mehy.2021.110537_b0100","doi-asserted-by":"crossref","first-page":"26486","DOI":"10.1016\/S0021-9258(18)47220-1","article-title":"Identification, cloning, and regulation of a novel endothelial cell protein C\/activated protein C receptor","volume":"269","author":"Fukudome","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.mehy.2021.110537_b0105","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1084\/jem.179.4.1253","article-title":"Elimination of interleukin-6 attenuates coagulation activation in experimental endotoxemia in chimpanzees","volume":"179","author":"Van der Poll","year":"1994","journal-title":"J Exp Med"},{"key":"10.1016\/j.mehy.2021.110537_b0110","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1749-6632.1986.tb34596.x","article-title":"Thrombin stimulates neutrophil adherence by an endothelial cell-dependent mechanism: characterization of the response and relationship to platelet-activating factor synthesis","volume":"485","author":"Zimmerman","year":"1986","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.mehy.2021.110537_b0115","doi-asserted-by":"crossref","unstructured":"Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 407.6801:258-64.","DOI":"10.1038\/35025229"},{"issue":"10","key":"10.1016\/j.mehy.2021.110537_b0120","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.4049\/jimmunol.160.10.5130","article-title":"Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation","volume":"160","author":"Johnson","year":"1998","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.mehy.2021.110537_b0125","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1006\/bcmd.1995.0018","article-title":"Thrombin enhances monocyte secretion of tumor necrosis factor and interleukin-1 beta by two distinct mechanisms","volume":"21","author":"Hoffman","year":"1995","journal-title":"Blood Cells Mol Dis"},{"issue":"7","key":"10.1016\/j.mehy.2021.110537_b0130","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1001\/archinte.1992.00400190023007","article-title":"Modulators of coagulation. A critical appraisal of their role in sepsis","volume":"152","author":"Bone","year":"1992","journal-title":"Arch Intern Med"},{"issue":"6","key":"10.1016\/j.mehy.2021.110537_b0135","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1172\/JCI116529","article-title":"Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock","volume":"91","author":"Creasey","year":"1993","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.mehy.2021.110537_b0140","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/00024382-199810000-00005","article-title":"Randomized, blinded, placebo-controlled trial of tissue factor pathway inhibitor in porcine septic shock","volume":"10","author":"Goldfarb","year":"1998","journal-title":"Shock (Augusta, Ga.)"},{"key":"10.1016\/j.mehy.2021.110537_b0145","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00281-011-0284-6","article-title":"Protein C anticoagulant system\u2014anti-inflammatory effects","volume":"34","author":"Esmon","year":"2012","journal-title":"Semin Immunopathol"},{"issue":"5","key":"10.1016\/j.mehy.2021.110537_b0150","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1182\/blood.V95.5.1680.005k33_1680_1686","article-title":"The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis","volume":"95","author":"Taylor","year":"2000","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.mehy.2021.110537_b0155","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S0002-9440(10)63401-3","article-title":"A protein C deficiency exacerbates inflammatory and hypotensive responses in mice during polymicrobial sepsis in a cecal ligation and puncture model","volume":"165","author":"Ganopolsky","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1016\/j.mehy.2021.110537_b0160","first-page":"L197","article-title":"Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production","volume":"272","author":"Murakami","year":"1997","journal-title":"Am J Physiol"},{"issue":"3","key":"10.1016\/j.mehy.2021.110537_b0165","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1172\/JCI112902","article-title":"Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon","volume":"79","author":"Taylor","year":"1987","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.mehy.2021.110537_b0170","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00281-011-0284-6","article-title":"Protein C anticoagulant system\u2013anti-inflammatory effects","volume":"34","author":"Esmon","year":"2012","journal-title":"Semin Immunopathol"},{"issue":"14","key":"10.1016\/j.mehy.2021.110537_b0175","doi-asserted-by":"crossref","first-page":"11199","DOI":"10.1074\/jbc.C100017200","article-title":"Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis","volume":"276","author":"Joyce","year":"2001","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.mehy.2021.110537_b0180","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1084\/jem.20020077","article-title":"The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways","volume":"196","author":"Conway","year":"2002","journal-title":"J Exp Med"},{"issue":"22","key":"10.1016\/j.mehy.2021.110537_b0185","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1202290","article-title":"Drotrecogin alfa (activated) in adults with septic shock","volume":"366","author":"Ranieri","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mehy.2021.110537_b0190","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1007\/s00134-008-1266-6","article-title":"Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock","volume":"34","author":"Finfer","year":"2008","journal-title":"Intensive Care Med"},{"issue":"9564","key":"10.1016\/j.mehy.2021.110537_b0195","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S0140-6736(07)60411-5","article-title":"Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial","volume":"369","author":"Nadel","year":"2007","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.mehy.2021.110537_b0200","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1056\/NEJMoa050935","article-title":"Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death","volume":"353","author":"Abraham","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mehy.2021.110537_b0205","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/bmj.1.5854.654","article-title":"Intravascular coagulation complicating influenza A virus infection","volume":"1","author":"Davison","year":"1973","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.mehy.2021.110537_b0210","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00467-003-1143-z","article-title":"Renal involvement in children with influenza A virus infection","volume":"18","author":"Watanabe","year":"2003","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"10.1016\/j.mehy.2021.110537_b0215","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1086\/314829","article-title":"Review: infectious diseases and coagulation disorders","volume":"180","author":"van Gorp","year":"1999","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.mehy.2021.110537_b0220","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.thromres.2010.11.032","article-title":"Serum D-dimer changes and prognostic implication in 2009 novel influenza A(H1N1)","volume":"127","author":"Wang","year":"2011","journal-title":"Thromb Res"},{"issue":"25","key":"10.1016\/j.mehy.2021.110537_b0225","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMra032498","article-title":"The severe acute respiratory syndrome","volume":"349","author":"Peiris","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mehy.2021.110537_b0230","unstructured":"Centers for Disease Control and Prevention (CDC). Update: Severe acute respiratory syndrome--United States, 2003. MMWR Morb Mortal Wkly Rep. 2003;52(16):357\u2013360."},{"key":"10.1016\/j.mehy.2021.110537_b0235","unstructured":"Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003, who.it, accessed at https:\/\/www.who.int\/csr\/sars\/country\/table2004_04_21\/en\/ on 6\/12\/2020."},{"issue":"9371","key":"10.1016\/j.mehy.2021.110537_b0240","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/S0140-6736(03)13412-5","article-title":"Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study","volume":"361","author":"Peiris","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.mehy.2021.110537_b0245","doi-asserted-by":"crossref","unstructured":"Gralinski LE, Bankhead A 3rd, Jeng S, et al. Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury. mBio 2013;4(4):e00271\u201313. Published 2013 Aug 6. doi:10.1128\/mBio.00271-13.","DOI":"10.1128\/mBio.00271-13"},{"issue":"6","key":"10.1016\/j.mehy.2021.110537_b0250","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.tim.2016.03.003","article-title":"Epidemiology, genetic recombination, and pathogenesis of coronaviruses","volume":"24","author":"Su","year":"2016","journal-title":"Trends Microbiol"},{"issue":"10229","key":"10.1016\/j.mehy.2021.110537_b0255","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S0140-6736(19)33221-0","article-title":"Middle East respiratory syndrome","volume":"395","author":"Memish","year":"2020","journal-title":"Lancet"},{"issue":"9997","key":"10.1016\/j.mehy.2021.110537_b0260","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(15)60454-8","article-title":"Middle East respiratory syndrome","volume":"386","author":"Zumla","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.mehy.2021.110537_b0265","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/cid\/ciu226","article-title":"Middle East respiratory syndrome coronavirus: a case-control study of hospitalized patients","volume":"59","author":"Al-Tawfiq","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.mehy.2021.110537_b0270","doi-asserted-by":"crossref","first-page":"389","DOI":"10.7326\/M13-2486","article-title":"Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection","volume":"160","author":"Arabi","year":"2014","journal-title":"Ann Intern Med"},{"issue":"Suppl 2","key":"10.1016\/j.mehy.2021.110537_b0275","doi-asserted-by":"crossref","first-page":"S390","DOI":"10.1086\/520598","article-title":"Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever","volume":"196","author":"Hensley","year":"2007","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.mehy.2021.110537_b0280","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/cmi.2016.10","article-title":"Arterial thrombosis in the context of HCV-associated vascular disease can be prevented by protein C","volume":"14","author":"Bl\u00fcm","year":"2017","journal-title":"Cell Mol Immunol"},{"issue":"10223","key":"10.1016\/j.mehy.2021.110537_b0285","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.mehy.2021.110537_b0290","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/jth.14768","article-title":"Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia","volume":"18","author":"Tang","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"11","key":"10.1016\/j.mehy.2021.110537_b0295","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China [published online ahead of print, 2020 Feb 7]","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.mehy.2021.110537_b0300","doi-asserted-by":"crossref","unstructured":"Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19 [published online ahead of print, 2020 May 15]. N Engl J Med 2020;10.1056\/NEJMcp2009575.","DOI":"10.1056\/NEJMcp2009575"},{"issue":"5","key":"10.1016\/j.mehy.2021.110537_b0305","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/jth.14817","article-title":"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy","volume":"18","author":"Tang","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.mehy.2021.110537_b0310","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.thromres.2020.04.013","article-title":"Incidence of thrombotic complications in critically ill ICU patients with COVID-19","volume":"191","author":"Klok","year":"2020","journal-title":"Thromb Res"},{"issue":"8","key":"10.1016\/j.mehy.2021.110537_b0315","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1111\/jth.14888","article-title":"Incidence of venous thromboembolism in hospitalized patients with COVID-19","volume":"18","author":"Middeldorp","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.mehy.2021.110537_b0320","article-title":"High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study [published online ahead of print, 2020 May 4]","volume":"1\u201310","author":"Helms","year":"2020","journal-title":"Intensive Care Med"},{"issue":"10234","key":"10.1016\/j.mehy.2021.110537_b0325","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","article-title":"Endothelial cell infection and endotheliitis in COVID-19","volume":"395","author":"Varga","year":"2020","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.mehy.2021.110537_b0330","doi-asserted-by":"crossref","first-page":"e575","DOI":"10.1016\/S2352-3026(20)30216-7","article-title":"Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study","volume":"7","author":"Goshua","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.mehy.2021.110537_b0335","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s00134-020-05991-x","article-title":"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China","volume":"46","author":"Ruan","year":"2020","journal-title":"Intensive Care Med"},{"issue":"10223","key":"10.1016\/j.mehy.2021.110537_b0340","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [published correction appears in Lancet. 2020 Jan 30;:]","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"10229","key":"10.1016\/j.mehy.2021.110537_b0345","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.mehy.2021.110537_b0350","unstructured":"WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, Alejandria MM, Hern\u00e1ndez Garc\u00eda C, Kieny MP, Malekzadeh R, Murthy S, Reddy KS, Roses Periago M, Abi Hanna P, Ader F, Al-Bader AM, Alhasawi A, Allum E, Alotaibi A, Alvarez-Moreno CA, Appadoo S, Asiri A, Aukrust P, Barratt-Due A, Bellani S, Branca M, Cappel-Porter HBC, Cerrato N, Chow TS, Como N, Eustace J, Garc\u00eda PJ, Godbole S, Gotuzzo E, Griskevicius L, Hamra R, Hassan M, Hassany M, Hutton D, Irmansyah I, Jancoriene L, Kirwan J, Kumar S, Lennon P, Lopardo G, Lydon P, Magrini N, Maguire T, Manevska S, Manuel O, McGinty S, Medina MT, Mesa Rubio ML, Miranda-Montoya MC, Nel J, Nunes EP, Perola M, Portol\u00e9s A, Rasmin MR, Raza A, Rees H, Reges PPS, Rogers CA, Salami K, Salvadori MI, Sinani N, Sterne JAC, Stevanovikj M, Tacconelli E, Tikkinen KAO, Trelle S, Zaid H, R\u00f8ttingen JA, Swaminathan S. Repurposed antiviral drugs for Covid-19 - Interim WHO solidarity trial results. N Engl J Med. 2020 Dec 2."},{"issue":"12","key":"10.1016\/j.mehy.2021.110537_b0355","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1055\/s-0040-1716544","article-title":"Derivation and validation of a predictive score for disease worsening in patients with COVID-19","volume":"120","author":"Gerotziafas","year":"2020","journal-title":"Thromb Haemost"},{"issue":"42","key":"10.1016\/j.mehy.2021.110537_b0360","doi-asserted-by":"crossref","first-page":"7479","DOI":"10.2174\/1381612819666131230131454","article-title":"Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteers","volume":"19","author":"Lyden","year":"2013","journal-title":"Curr Pharm Des"},{"issue":"1","key":"10.1016\/j.mehy.2021.110537_b0365","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ana.25383","volume":"85","author":"Lyden","year":"2019","journal-title":"Ann Neurol"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987721000554?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987721000554?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:24:08Z","timestamp":1759692248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987721000554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":73,"alternative-id":["S0306987721000554"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2021.110537","relation":{},"ISSN":["0306-9877"],"issn-type":[{"type":"print","value":"0306-9877"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Old drug, new Trick? The rationale for the treatment of COVID-19 with activated protein C","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2021.110537","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110537"}}